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Background: Intravenous Immunoglobulins (IVIg) represent a relevant treatment option in various 
immune-mediated disorders such as idiopathic inflammatory muscle diseases (IIMD), immune-
mediated chronic neuropathies (IMCN), hematologic autoimmune diseases, Still disease, Felty 
syndrome, systemic lupus erythematosus, vasculitis, some organ-specific autoimmune disease, and 
atopic diseases. The IVIg treatment is expensive and need of hospital-based assistance for 
administration; the recent avaibility of home-therapy with subcutaneous immunoglobulins (SCIg) 
may significantly reduce costs and improve the patient's quality of life. 
Objectives: The primary objective was to perform an analysis of costs of SCIg administration in 
patients affected by IIMD or IMCN compared to that of previous IVIg treatments. 
Methods: We prospectively evaluated 6 consecutive patients (3 males and 3 females, mean age 
65,3 years, range 63 - 77), 2 affected by IIMD in the context of polymiositis and 4 by IMCN, 3 in 
the context of vasculitis and 1 in the context of undifferentiated connective tissue disease. All 
patients were previously treated with IVIg at the dosage of 2g/Kg monthly, (mean monthly dosage 
143 g, range 98 – 160, average patient weight 71,5 kg, range 49 - 80), with good clinical and 
humoral response. After a mean therapy duration of 49.8 months (range 12 – 125) all patients were 
shifted to SCIg at the dosage of 10 g twice a week (80 g monthly). Each patient was followed-up by 
humoral and clinical evaluation, including Medical Research Council (MRC) score to quantify 
muscle strength and INCAT Sensory Score to evaluate sensory symptoms. The costs of the two 
therapeutic strategies were also compared, excluding indirect costs (absences from work and 
productivity losses, transport and parking, health care sector costs). 
Results: In 5/6 patients, we observed the maintenance of clinical and humoral status after a mean 
follow-up of 21 months (range 4 - 51), in particular we observed a stability in MRC score in 
patients presenting loss of strenght and INCAT score in patients presenting sensory symptoms. 
Furthermore, the treatment with SCIg was well-accepted and preferred to IVIg by all patients. In 
one patient SCIg were discontinued after 2 weeks, because of the appearance of a haemorrhagic 
lesions nearby the injection site (in the same patient IVIg have been stopped because of a 
hypertensive crisis during the infusion). Direct cost associated to IVIg amount to 252€ for 5 g of 
immunoglobulins (7,056€ monthly, considering a protocol of 2 g/kg/monthly and a patient-weight 
of 70kg), while direct costs associated to SCIg (20g weekly) amount to 6,400€/monthly, with a 
saving of 656€/monthly and 7,872€/yearly. In our case-series the annual saving was 
9,686.40€/patient (from 86,486.40€ to 76,800€, for IVIg and SCIg, respectively). 
Conclusions: Our experience suggests that the shift to SCIg from IVIg in patients affected by IIMD 
and IMCN is feasible, cost-effective, safe and well-accepted by patients. Further studies are needed 
to evaluate the effectiveness of SCIg in first-line therapy of these diseases. 
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